Selected article for: "acute respiratory distress syndrome and adaptive immune system"
Author: Rao US, Vishal; Thakur, Shalini; Rao, Jyothsna; Arakeri, Gururaj; Brennan, Peter A; Jadhav, Sachin; Suhail Sayeed, Mufti; Rao, Gururaj
Title: Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19
  • Cord-id: vqpwdlj7
  • Document date: 2020_5_18
    • ID: vqpwdlj7
    Snippet: Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14 - 20 days,. However, about 15 % of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (< 65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early
    Document: Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14 - 20 days,. However, about 15 % of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (< 65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and acute ards respiratory distress syndrome lead: 1
    • absence presence and adaptive immune response: 1, 2
    • absence presence and adaptive immune system: 1
    • absence presence and adaptive immunity: 1, 2, 3, 4
    • absence presence and low expression: 1, 2, 3
    • absence presence and lung alveolar: 1, 2, 3
    • activation proliferation and acute ards respiratory distress syndrome: 1, 2
    • activation proliferation and adaptive immune cell: 1, 2
    • activation proliferation and adaptive immune response: 1, 2
    • activation proliferation and adaptive immunity: 1, 2, 3, 4, 5
    • activation proliferation and low expression: 1
    • acute ards respiratory distress syndrome and adaptive immune cell: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immune system: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low expression: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung alveolar epithelial cell: 1, 2, 3, 4, 5